Resources Repository
-
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Priority Setting/Ethics | North America | Infectious Diseases | Preferences/Values | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Europe -
ReviewPublication 2016Strengthening Cost-Effectiveness Analysis for Public Health Policy
Many important opportunities to improve health lie outside the health sector and involve improving the …
Many important opportunities to improve health lie outside the health sector and involve improving the conditions in which we live and work: safe design and maintenance of roads, bridges, train tracks, and airports; control of environmental pollutants; occupational safety; healthy buildings; a safe and healthy food supply; safe manufacture of consumer products; a healthy social environment; and others. Faced with the overwhelming array of possibilities, U.S. decision makers need help identifying those that can contribute the…
Priority Setting/Ethics | North America | Environmental Health | Preferences/Values | Costing Methods | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Policy/Regulation | Climate/Environment | Economics/Finance | Food/Agriculture | Health/Medicine -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Priority Setting/Ethics | North America | Infectious Diseases | Cost-Effectiveness Analysis | Technology Assessment | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ReviewPublication 2013Role of Health Economic Analyses in Vaccine Decision Making
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in …
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, cost effectiveness became a topic of discussion when a vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the U.S. Institute of Medicine has recommended that health economic considerations play a…
Priority Setting/Ethics | North America | Infectious Diseases | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Priority Setting/Ethics | North America | Environmental Health | Evidence Synthesis | Mathematical Models | Technology Assessment | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine